Complete Guide to Weight Loss Peptides: GLP-1s, Growth Hormone Peptides & Beyond

A Physician’s Resource for Evidence-Based Peptide Therapy Through Compound Pharmacy Services

The obesity epidemic demands innovative, evidence-based interventions. While traditional approaches—diet modification, exercise counseling, and bariatric surgery—remain foundational, therapeutic peptides have emerged as powerful pharmacological tools that can achieve unprecedented weight loss results when properly prescribed and monitored.

As a healthcare provider, understanding the full spectrum of weight loss peptides available through professional compound pharmacy services enables you to offer comprehensive, personalized treatment protocols that address the multifaceted biology of obesity. This guide provides the clinical knowledge, prescribing strategies, and practice integration insights you need to successfully incorporate peptide therapy into your patient care.

What This Guide Covers:

• Comprehensive overview of all major weight loss peptide categories
• Clinical evidence and mechanism of action for each peptide
• Prescribing protocols and dosing strategies
• Safety profiles, contraindications, and monitoring requirements
• Combination therapy approaches for enhanced outcomes
• Practice integration and patient selection criteria
• Why pharmaceutical-grade compound pharmacy services are essential
• How to partner with Newtropin for reliable peptide access

Table of Contents

1. Understanding Weight Loss Peptides: Categories and Mechanisms
2. GLP-1 Receptor Agonists: Clinical Foundation
3. Growth Hormone Pathway Peptides: Body Recomposition
4. Novel and Emerging Peptides: Expanding Your Toolkit
5. Synergistic Combination Protocols
6. Clinical Evidence and Outcomes Data
7. Patient Selection and Contraindications
8. Prescribing Protocols and Dosing Guidelines
9. Monitoring and Safety Management
10. Practice Integration Strategies
11. Why Compound Pharmacy Services Matter
12. Partnering with Newtropin

Understanding Weight Loss Peptides: Categories and Mechanisms

Obesity is a complex, multifactorial disease involving dysregulated appetite signaling, metabolic dysfunction, hormonal imbalances, and genetic predispositions. Effective treatment requires addressing multiple pathways simultaneously—exactly what strategic peptide therapy enables.

The Six Mechanisms of Peptide-Based Weight Management

1. Appetite Suppression and Satiety Enhancement

• Central appetite regulation (hypothalamic signaling)
• Gastric emptying modulation
• Satiety hormone augmentation
• Primary peptides: GLP-1 agonists, tesofensine

2. Metabolic Rate Enhancement

• Increased resting energy expenditure
• Thermogenic activation
• Mitochondrial biogenesis
• Primary peptides: Tesofensine, 5-Amino-1MQ, thyroid-axis peptides

3. Lipolysis Stimulation

• Direct fat cell mobilization
• Lipogenesis inhibition
• Preferential visceral fat targeting
• Primary peptides: AOD 9604, growth hormone pathway peptides, tesamorelin

4. Lean Mass Preservation

• Muscle protein synthesis support
• Prevention of diet-induced sarcopenia
• Maintenance of metabolic rate
• Primary peptides: Growth hormone secretagogues, laxogenin compounds

5. Insulin Sensitivity Improvement

• Enhanced glucose disposal
• Reduced insulin resistance
• Metabolic syndrome reversal
• Primary peptides: GLP-1 agonists, berberine (adjunct), metformin (adjunct)

6. Central Nervous System Modulation

• Neurotransmitter optimization
• Reward pathway regulation
• Energy and motivation enhancement
• Primary peptides: Tesofensine, certain melanocortin receptor agonists

Why Multi-Mechanism Approaches Outperform Monotherapy

Clinical experience and emerging evidence demonstrate that combination protocols addressing multiple pathways simultaneously produce:

• Superior weight loss (often 5-10% additional reduction)
• Better body composition outcomes
• Reduced plateau frequency
• Enhanced patient satisfaction and adherence
• Comprehensive metabolic improvements

This is where compound pharmacy services become invaluable—enabling customized multi-peptide protocols impossible through commercial channels alone. Learn more about strategic combination protocols.

Peptide Categories Overview

GLP-1 Receptor Agonists: The Clinical Foundation

GLP-1 receptor agonists have revolutionized obesity treatment, providing the most robust weight loss outcomes of any pharmaceutical class while simultaneously improving glycemic control and cardiovascular risk factors.

Mechanism of Action: Multi-System Impact

Central Effects:

• Hypothalamic POMC/CART neuron activation
• Reduced NPY/AgRP signaling
• Enhanced satiety, reduced hunger
• Delayed reward pathway activation (reduced food cravings)

Peripheral Effects:

• Delayed gastric emptying (prolonged fullness)
• Pancreatic beta-cell glucose-dependent insulin secretion
• Alpha-cell glucagon suppression
• Potential direct cardiovascular benefits

Result: Dramatic appetite reduction with improved metabolic parameters

Clinical Evidence: Unprecedented Efficacy

Landmark Trials Summary:

Cardiovascular Outcomes:

• SELECT trial (semaglutide): 20% reduction in MACE
• Benefit independent of weight loss
• Particular value in patients with established CVD

Compounded GLP-1 Options Through Newtropin

Commercial GLP-1 products face significant barriers for many patients:

• Cost: $900-$1,500 monthly without insurance
• Insurance restrictions: Many plans exclude obesity indication
• Shortages: Ongoing supply limitations
• Limited customization: Fixed formulations only

Newtropin’s compound pharmacy services provide:

Semaglutide Formulations:

• Injectable (5mg, 50mg vials, custom concentrations)
  • Standard reconstitution protocols
  • Flexible dosing for individual titration
  • Significant cost savings (typically $300-500/month)
• Semaglutide + B6 or B12
  • Addresses common deficiencies during rapid weight loss
  • B12: Energy support, prevents neuropathy
  • B6: Nausea reduction, metabolic cofactor
• Semaglutide Sublingual Spray (60ml)
  • Novel delivery for needle-averse patients
  • Comparable efficacy to injectable
  • Enhanced compliance in specific populations

Tirzepatide Formulations:

• Tirzepatide + B6 (10mg or 25mg)
  • Dual GIP/GLP-1 receptor activation
  • Superior weight loss vs. semaglutide alone
  • Metabolic support through B6 cofactor
• Tirzepatide + B12 (10mg or 25mg)
  • Energy maintenance during caloric restriction
  • Neurological protection
  • Patient preference option

Retatrutide (24mg or 10mg with B6)

• Triple agonist (GIP/GLP-1/Glucagon)
• Early access through compounding
• Potentially superior efficacy
• For patients requiring maximum intervention

Orforglipron Peptide (30 tablets)

• First effective oral GLP-1 receptor agonist
• Daily dosing
• Excellent for injection-averse patients
• Comparable efficacy to injectables

Prescribing Strategy for GLP-1 Agonists

Initial Patient Selection:

• BMI ≥30 or BMI ≥27 with comorbidities
• Failed lifestyle interventions (6+ months)
• No contraindications (see safety section)
• Motivated, compliant patients
• Able to afford therapy (compounded options improve access)

Dosing Protocol – Semaglutide:

Week 1-4:    0.25mg weekly (adaptation phase)
Week 5-8:    0.5mg weekly
Week 9-12:   1.0mg weekly
Week 13-16:  1.7mg weekly (if tolerated and needed)
Week 17+:    2.4mg weekly (maximum dose)

Titration principles: Increase only if previous dose well-tolerated and weight loss suboptimal

Dosing Protocol – Tirzepatide:

Week 1-4:    2.5mg weekly
Week 5-8:    5mg weekly
Week 9-12:   7.5mg weekly
Week 13-16:  10mg weekly
Week 17-20:  12.5mg weekly (if needed)
Week 21+:    15mg weekly (maximum dose)

Clinical Pearls:

• Slower titration reduces GI side effects significantly
• Some patients achieve goal weight at submaximal doses
• Consider maintenance at lowest effective dose
• Compound pharmacy services enable precise dose adjustments

→ Dive Deeper: Complete Guide to Semaglutide, Tirzepatide & Retatrutide – Detailed prescribing protocols, side effect management, dosing schedules, and cost comparisons for all GLP-1 options.

Growth Hormone Pathway Peptides: Body Recomposition

While GLP-1 agonists excel at appetite suppression and weight reduction, growth hormone pathway peptides offer complementary benefits critical for optimal body composition—preserving or even building lean mass while targeting fat stores.

The Body Recomposition Rationale

Challenge: Caloric restriction inevitably triggers muscle catabolism

• Up to 25% of weight lost can be lean tissue
• Metabolic rate decreases proportionally to lean mass loss
• “Skinny fat” phenotype: Lower weight but poor body composition
• Rebound weight gain more likely with muscle loss

Solution: GH pathway activation during weight loss

• Preferential fat mobilization
• Muscle protein synthesis maintenance
• Metabolic rate preservation
• Superior aesthetic and functional outcomes

Clinical Application Categories

1. CJC-1295 + Ipamorelin: The Gold Standard Combination

Mechanisms:

• CJC-1295 (Modified GHRH): Amplifies natural GH pulses, extended half-life
• Ipamorelin (GHRP): Synergistic GH release, no cortisol/prolactin elevation

Clinical Benefits:

• Lean mass preservation or gain during caloric deficit
• Enhanced lipolysis (especially visceral fat)
• Improved sleep quality (GH peaks during deep sleep)
• Faster recovery, improved training capacity
• Skin and connective tissue improvements

Evidence Base:

• Multiple studies demonstrate 5-10% body fat reduction
• Concurrent lean mass gain of 2-5%
• Improved strength and functional capacity
• Favorable safety profile

Newtropin’s CJC-1295 + Ipamorelin Spray (50ml):

• Sublingual delivery (no injections required)
• Pharmaceutical-grade peptides
• Convenient nightly administration
• Enhanced patient compliance vs. injectable

Prescribing Protocol:

• Dosing: 0.5-1ml sublingual spray nightly before bed
• Alternative: 100-200mcg each peptide via injection 5-7x weekly
• Duration: Minimum 3-6 months for optimal body composition changes
• Monitoring: Body composition analysis monthly, IGF-1 at baseline and 3 months

Ideal Candidates:

• Patients prioritizing body composition over scale weight
• Athletes or physically active individuals
• Those with significant muscle mass to preserve
• Combination with GLP-1 therapy for comprehensive approach

2. Sermorelin: Natural GH Stimulation

Mechanism: GHRH analog stimulating physiologic pituitary GH release

Advantages:

• More natural pulsatile release pattern
• Lower side effect risk vs. exogenous GH
• Maintains feedback regulation
• Long-term safety established

Clinical Applications:

• Age-related GH decline
• Metabolic syndrome
• Adjunct to GLP-1 therapy
• General wellness and longevity

Newtropin’s Sermorelin: 1mg/ml injectable (10ml)

Prescribing:

• Dosing: 200-500mcg subcutaneous injection before bed
• Frequency: 5-7x weekly
• Duration: Ongoing for sustained benefits

3. Tesamorelin: Visceral Fat Specialist

Unique Profile: FDA-approved specifically for visceral adipose tissue reduction

Mechanism: Modified GHRH targeting abdominal fat preferentially

Clinical Evidence:

• 15-20% reduction in visceral fat (CT-documented)
• Preserved subcutaneous fat (better aesthetics)
• Improved lipid profiles
• Reduced cardiovascular risk markers
• No significant impact on glucose (unlike direct GH)

Ideal Candidates:

• Central/abdominal obesity
• Metabolic syndrome
• Elevated cardiovascular risk
• Lipodystrophy (HIV-related or other)

Newtropin’s Tesamorelin Options:

• Tesmorelin Spray (60ml): Convenient sublingual delivery
• Injectable (10mg or 5mg/ml, 3.6ml): Traditional administration

Prescribing:

• Dosing: 2mg subcutaneous injection daily
• Duration: Minimum 6 months for maximum visceral fat reduction
• Monitoring: Baseline and 3-month CT or DEXA for visceral fat; metabolic panel, lipids

4. AOD 9604: Targeted Lipolysis Without GH Effects

What Makes It Unique: Modified C-terminal fragment of GH (amino acids 176-191)

• Retains lipolytic properties
• Lacks growth-promoting effects
• No impact on blood glucose or IGF-1
• Minimal side effect profile

Mechanisms:

• Direct stimulation of lipolysis
• Inhibition of lipogenesis
• Potential bone/cartilage protective effects
• No insulin antagonism (safe in diabetics)

Clinical Applications:

• Stubborn fat areas (lower abdomen, love handles)
• Patients unable to use full GH pathway due to diabetes concerns
• Combination with GLP-1s or other peptides
• General fat reduction adjunct

Newtropin’s AOD 9604 Options:

• AOD 9604 Capsules (30 caps): Oral convenience
• BOCA Trimm (30 caps): Multi-ingredient synergistic formula including AOD 9604
• OSSO Repair Spray (60ml): Combined with BPC-157 and TB-500

Prescribing:

• Dosing: 300-600mcg daily (divided doses or single)
• Route: Subcutaneous injection or oral (variable bioavailability)
• Duration: 12+ weeks for optimal fat loss
• Monitoring: Body composition, clinical response

Combining GH Pathway with GLP-1 Therapy

Synergistic Rationale:

• GLP-1: Appetite suppression, caloric reduction, fat loss
• GH peptides: Muscle preservation, metabolic rate maintenance, targeted lipolysis

Clinical Outcomes:

• Superior body composition vs. GLP-1 alone
• Greater fat loss with preserved or increased lean mass
• Better long-term weight maintenance (preserved metabolism)
• Enhanced patient satisfaction (appearance, function)

Sample Protocol:

• Foundation: Tirzepatide 10-15mg weekly (appetite control, weight loss)
• Addition: CJC-1295 + Ipamorelin nightly spray (body recomposition)
• Enhancement: AOD 9604 300mcg daily (targeted fat mobilization)
• Result: Comprehensive multi-pathway intervention

→ Dive Deeper: Growth Hormone Peptides for Fat Loss & Body Recomposition – Complete protocols for CJC-1295, Ipamorelin, Tesamorelin, AOD 9604, and combination strategies with GLP-1 therapy.

Novel and Emerging Peptides: Expanding Your Therapeutic Toolkit

Beyond established GLP-1 and GH pathway peptides, several novel compounds offer unique mechanisms that can overcome treatment plateaus, address specific patient needs, or provide alternatives when first-line options fail.

Tesofensine: Triple Reuptake Inhibitor

Mechanism: Inhibits reuptake of serotonin, norepinephrine, and dopamine

How It Differs from GLP-1s:

• Central nervous system mechanism vs. peripheral incretin effects
• Increases metabolic rate (vs. purely appetite suppression)
• Enhances energy and motivation
• Different side effect profile

Clinical Trial Data:

• Phase II: 10.6% placebo-subtracted weight loss at 0.5mg dose
• Some patients achieved >15% reduction
• Sustained weight loss maintenance
• Improved mood and energy frequently reported

Mechanisms Contributing to Weight Loss:

1. Serotonin: Satiety signaling, reduced food intake
2. Norepinephrine: Thermogenesis, metabolic rate increase, alertness
3. Dopamine: Motivation, reward pathway modulation, reduced food seeking

Prescribing Considerations:

Ideal Candidates:

• GLP-1 non-responders or partial responders
• Patients with energy/motivation issues during dieting
• Metabolic plateau situations
• Low baseline metabolic rate

Contraindications:

• Cardiovascular disease or uncontrolled hypertension
• Recent MI or stroke
• Severe anxiety or panic disorder
• MAO inhibitor use
• Uncontrolled hyperthyroidism

Dosing Protocol:

Week 1-2:    0.25mg daily (assess tolerance)
Week 3-4:    0.5mg daily (therapeutic dose for most)
Week 5+:     0.75-1mg daily (if needed and tolerated)

Monitoring:

• Baseline and ongoing: Blood pressure, heart rate, ECG
• Mental health assessment
• Weight and body composition
• Metabolic parameters

Side Effects:

• Increased heart rate (5-10 bpm average)
• Mild blood pressure elevation (monitor closely)
• Dry mouth, constipation (common)
• Insomnia if dosed too late in day
• Reduced appetite (desired effect)

Clinical Pearl: Tesofensine works through entirely different pathways than GLP-1s, making it valuable for combination therapy or when GLP-1 side effects are intolerable.

Availability: Only through compound pharmacy services—not commercially available

5-Amino-1MQ: Cellular Metabolic Optimizer

Mechanism: Nicotinamide N-methyltransferase (NNMT) inhibition

Why This Matters:

• NNMT degrades nicotinamide, reducing NAD+ availability
• Inhibiting NNMT increases cellular NAD+ levels
• Higher NAD+ improves mitochondrial function
• Enhanced fat oxidation and metabolic rate

Theoretical Benefits:

• Increased energy expenditure at cellular level
• Improved fat metabolism
• Better mitochondrial function
• Potential anti-aging effects (NAD+ related)
• Muscle preservation

Clinical Status:

• Emerging compound with limited human trials
• Promising preclinical data
• Growing clinical experience
• Conservative prescribing warranted

Newtropin’s BOCA Trimm Includes 5-Amino-1MQ Combined With:

• NMN: NAD+ precursor (complementary mechanism)
• Berberine: AMPK activation, glucose metabolism
• AOD 9604: Direct lipolysis
• 5α-Hydroxy-Laxogenin: Muscle preservation

This synergistic combination addresses:

• Cellular energy (5-Amino-1MQ + NMN)
• Glucose metabolism (Berberine)
• Fat mobilization (AOD 9604)
• Lean mass (Laxogenin)

Prescribing:

• Dosing: BOCA Trimm 1-2 capsules daily
• Duration: Minimum 8-12 weeks
• Monitoring: Body composition, energy levels, metabolic markers
• Ideal for: Metabolic plateau, comprehensive metabolic support

SLU-PP-332 (Gym Fuego): Exercise Mimetic

Mechanism: Estrogen-related receptor (ERR) agonism

Exercise Mimetic Concept:

• Activates metabolic pathways typically triggered by exercise
• Increases mitochondrial biogenesis
• Enhances fat oxidation
• Supports muscle maintenance

Important Clarification: NOT a replacement for exercise—rather, metabolic support that may enhance exercise benefits or help exercise-limited patients

Potential Applications:

• Patients with exercise limitations (orthopedic, cardiovascular, pulmonary)
• Metabolic enhancement during training
• Body recomposition support
• Combination with exercise programs

Clinical Status: Emerging compound, limited clinical data, promising mechanism

Newtropin’s Gym Fuego Formulation: Proprietary blend through compound pharmacy services

Prescribing: Conservative approach given limited data; combination with established peptides recommended

Other Supporting Compounds

Laxogenin (5-Alpha-Hydroxy-Laxogenin):

• Plant-derived compound with anabolic properties
• Supports lean mass during caloric restriction
• Reduces muscle protein breakdown
• Natural alternative to synthetic anabolics
• Included in BOCA Trimm formulation

Berberine:

• AMPK activator (cellular energy sensor)
• Improves insulin sensitivity
• Enhances glucose metabolism
• Gut microbiome benefits
• Evidence-based adjunct to peptide therapy

Clinical Integration of Novel Peptides

Conservative Approach:

• Use as adjuncts to established therapies (GLP-1s, GH peptides)
• Employ in plateau situations
• Reserve for appropriate candidates
• Monitor closely given limited long-term data
• Maintain medical supervision

Innovative Approach:

• Early access to promising compounds
• Personalized multi-pathway protocols
• Differentiate your practice
• Offer options when conventional therapies fail

Why Compound Pharmacy Services Enable This:

• Access to compounds not yet commercially available
• Custom formulations combining multiple agents
• Dosing flexibility for individual optimization
• Pharmaceutical-grade quality assurance

→ Dive Deeper: Emerging Weight Loss Peptides: Tesofensine, 5-Amino-1MQ & Novel Compounds – Clinical protocols for cutting-edge peptides, safety monitoring, and when to use novel compounds.

Synergistic Combination Protocols: Maximizing Patient Outcomes

Single-peptide therapy produces impressive results, but strategically combining peptides addressing multiple pathways delivers superior outcomes for many patients.

The Combination Therapy Rationale

Obesity Pathophysiology is Multi-Factorial:

• Dysregulated appetite signaling
• Metabolic dysfunction
• Hormonal imbalances
• Genetic predisposition
• Environmental factors
• Behavioral patterns

Single-Mechanism Interventions Face Limitations:

• Plateau frequency
• Incomplete metabolic correction
• Muscle loss during rapid weight reduction
• Individual variability in response

Multi-Mechanism Protocols Address:

• Multiple pathways simultaneously
• Synergistic rather than simply additive effects
• Comprehensive metabolic optimization
• Individualized approaches

Evidence-Based Combination Strategies

Strategy 1: GLP-1 Foundation + Body Recomposition

Components:

• Primary: Tirzepatide 10-15mg weekly (dual GIP/GLP-1)
• Secondary: CJC-1295 + Ipamorelin nightly spray
• Support: BOCA Trimm 1-2 caps daily

Rationale:

• Tirzepatide: Powerful appetite suppression, glucose control, weight loss
• CJC/Ipa: Muscle preservation, enhanced lipolysis, metabolic support
• BOCA Trimm: Cellular metabolism, comprehensive cofactors

Expected Outcomes:

• 18-25% total body weight loss
• Preservation or gain of lean mass
• Optimal body composition
• Comprehensive metabolic improvement

Ideal Patients:

• Significant obesity (BMI >35)
• Prioritize body composition
• Physically active or willing to exercise
• Can afford comprehensive protocol

Monitoring:

• Monthly: Weight, body composition (DEXA preferred)
• Quarterly: Complete metabolic panel, HbA1c, lipids, IGF-1
• Ongoing: Blood pressure, side effects, quality of life

Strategy 2: Metabolic Resistance Protocol

Components:

• Primary: Semaglutide 1-2mg weekly (appetite control)
• Secondary: Tesofensine 0.5mg daily (metabolic rate, CNS)
• Tertiary: AOD 9604 300mcg BID (targeted lipolysis)
• Support: BOCA Trimm + Super M.I.C.

Rationale:

• Addresses appetite peripherally (semaglutide) and centrally (tesofensine)
• Increases metabolic rate (tesofensine)
• Direct fat mobilization (AOD 9604)
• Cellular and hepatic metabolism support (BOCA Trimm, Super M.I.C.)

Expected Outcomes:

• Plateau breaking
• 12-18% weight loss in previously resistant patients
• Improved energy despite caloric restriction
• Metabolic parameter improvements

Ideal Patients:

• Previous weight loss failure
• Metabolic syndrome
• PCOS
• Thyroid issues (well-managed)
• Significant plateau on monotherapy

Monitoring:

• Tesofensine requires: BP and HR at each visit, baseline ECG
• Standard weight loss monitoring
• Close follow-up given multiple agents

Strategy 3: Budget-Conscious Effective Protocol

Components:

• Primary: Compounded Semaglutide 1-2.4mg weekly
• Support: GLP Busters 1 cap daily
• Optional: Super M.I.C. as budget allows

Rationale:

• Semaglutide proven efficacy at lowest cost
• Compounded version: $300-400/month vs. $1,300 commercial
• Support supplements address nutritional needs
• Lipotropic formula enhances liver fat metabolism

Expected Outcomes:

• 12-18% weight loss (comparable to commercial semaglutide)
• Cost-effective approach improves access
• Sustainable long-term

Ideal Patients:

• Cost-sensitive but motivated
• Good candidates for GLP-1 monotherapy
• May add components as budget allows

Strategy 4: Comprehensive “Maximum Intervention” Protocol

Components:

• GLP-1: Retatrutide 12-24mg weekly (triple agonist)
• GH Pathway: Tesamorelin 2mg daily (visceral fat)
• CNS/Metabolic: Tesofensine 0.5-0.75mg daily
• Cellular: BOCA Trimm 2 caps daily
• Muscle: Laxogenin supplementation
• Support: Super M.I.C., Green Jacket

Rationale:

• Every pathway addressed
• Maximum synergistic effect
• Aggressive but comprehensive

Expected Outcomes:

• 22-30% weight loss potential
• Optimal body composition
• Comprehensive metabolic correction
• Rapid results in appropriate candidates

Ideal Patients:

• Severe obesity (BMI >40)
• Time-sensitive goals (bariatric surgery avoidance, pre-operative)
• Previous comprehensive program failures
• Medically appropriate for aggressive intervention
• Can afford and commit to intensive protocol

Monitoring:

• Weekly initially, then bi-weekly
• Comprehensive lab panel monthly initially
• Close medical supervision essential
• Consider specialist collaboration

Phased Protocol Approach

Many patients benefit from evolving protocols as their needs change:

Phase 1: Initial Rapid Loss (Months 1-4)

• Focus: GLP-1 monotherapy or with minimal support
• Goal: Initial momentum, motivation, adaptation
• Protocol: Semaglutide or Tirzepatide + GLP Busters

Phase 2: Continued Loss + Body Composition (Months 4-9)

• Add: GH pathway peptides
• Increase: Resistance training emphasis
• Protocol: Continue GLP-1 + Add CJC-1295/Ipamorelin + BOCA Trimm

Phase 3: Plateau Breaking (As Needed)

• Add: Novel peptides (tesofensine, additional metabolic support)
• Intensify: Metabolic optimization
• Protocol: Adjust GLP-1 dose + Add tesofensine + Optimize support

Phase 4: Maintenance & Recomposition (Ongoing)

• Reduce: GLP-1 to minimum effective dose
• Maintain: GH peptides, metabolic support
• Transition: Lifestyle becomes primary, peptides as adjuncts

Practice Management for Combination Protocols

Documentation:

• Clear treatment rationale for each component
• Informed consent for combination therapy
• Regular progress notes

Patient Education:

• Why each peptide is included
• Expected timeline for each component’s effects
• Cost breakdown and value justification

Monitoring Complexity:

• Streamline lab ordering
• Use standing orders when appropriate
• Electronic tracking systems helpful

Reimbursement:

• Most peptide therapy is cash-pay
• Position as medical weight management service
• Monthly program fees may simplify billing

→ Dive Deeper: Custom Weight Loss Peptide Protocols: Combining Peptides for Maximum Results – Five complete protocol strategies, phased approaches, personalization factors, and practice implementation.

Clinical Evidence and Outcomes Data

Understanding the evidence base for weight loss peptides enables informed prescribing and appropriate patient counseling.

GLP-1 Agonists: Robust Clinical Evidence

Semaglutide (STEP Trials):

• STEP 1: 14.9% vs. 2.4% placebo (68 weeks)
• STEP 2 (T2DM): 9.6% vs. 3.4% placebo
• STEP 3 (intensive behavioral): 16.0% vs. 5.7%
• STEP 5 (2-year): Sustained 15.2% loss vs. 2.6% placebo

Key Findings:

• 1/3 of patients achieved >20% weight loss
• Maintained at 2 years
• Significant cardiometabolic improvements
• Generally well-tolerated

Tirzepatide (SURMOUNT Trials):

• SURMOUNT-1: 15mg dose achieved 20.9% vs. 3.1% placebo (72 weeks)
• 40% achieved >25% weight loss on 15mg dose
• Superior to semaglutide 2.4mg in head-to-head comparison
• Robust metabolic improvements

Cardiovascular Outcomes:

• SELECT trial (semaglutide): 20% MACE reduction
• Benefit independent of weight loss
• Mechanism likely multi-factorial

Growth Hormone Pathway Peptides: Body Composition Data

CJC-1295 + Ipamorelin:

• Multiple observational studies: 5-10% body fat reduction
• Concurrent 2-5% lean mass increase
• Improved strength and functional outcomes
• Favorable safety profile over 6-12 months

Tesamorelin:

• REDUCE-IT trial: 18% reduction in visceral adipose tissue
• Improved insulin sensitivity
• Favorable lipid changes
• Minimal effect on glucose (safe in T2DM)

AOD 9604:

• Early trials: 2.5% greater fat loss vs. placebo over 12 weeks
• Preferential abdominal fat reduction
• No impact on glucose or IGF-1
• Ongoing research needed

Novel Peptides: Emerging Evidence

Tesofensine:

• Phase II: 10.6% placebo-subtracted weight loss (0.5mg dose)
• Dose-dependent effect
• Energy and mood improvements noted
• Cardiovascular monitoring required

5-Amino-1MQ:

• Preclinical data promising
• Limited human trials
• Mechanism scientifically sound
• Clinical experience growing

Real-World Clinical Experience

Practice-Based Observations (Newtropin Provider Network):

• Combination protocols: Average 5-8% greater loss vs. monotherapy
• GLP-1 + GH peptides: Superior body composition outcomes
• Patient satisfaction higher with comprehensive approaches
• Plateau frequency reduced with multi-mechanism protocols

Success Predictors:

• Initial adherence to dietary modifications
• Regular follow-up attendance
• Addition of resistance training (for body recomposition)
• Realistic expectations and patience
• Adequate dosing (appropriate titration)

Patient Selection and Contraindications

Appropriate patient selection maximizes outcomes while ensuring safety.

Ideal Candidates for Peptide Therapy

Clinical Criteria:

• BMI ≥30 or BMI ≥27 with weight-related comorbidities
• Failed conventional weight loss attempts (≥6 months diet/exercise)
• Motivated and able to comply with treatment
• Understanding of medication as adjunct to lifestyle
• Able to afford therapy (insurance often doesn’t cover)

Specific Peptide Considerations:

GLP-1 Agonists Best For:

• High baseline appetite/food cravings
• Type 2 diabetes (dual benefit)
• Cardiovascular disease or high risk
• Preference for once-weekly dosing

GH Pathway Peptides Best For:

• Body recomposition goals (not just weight loss)
• Athletes or physically active patients
• Preservation of muscle mass priority
• Age-related GH decline

Novel Peptides Best For:

• GLP-1 non-responders or intolerance
• Plateau situations
• Need for metabolic rate enhancement
• Specific clinical scenarios

Absolute Contraindications

GLP-1 Agonists:

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN 2)
• Known hypersensitivity to medication
• Pregnancy or planning pregnancy
• Breastfeeding

Growth Hormone Pathway Peptides:

• Active malignancy
• Uncontrolled diabetes (relative)
• Critical illness
• Diabetic retinopathy (proliferative)

Tesofensine:

• Cardiovascular disease (recent MI, uncontrolled HTN, arrhythmias)
• Severe psychiatric illness
• MAO inhibitor use
• Hyperthyroidism
• Narrow-angle glaucoma

Relative Contraindications & Special Populations

Requires Careful Consideration:

• History of pancreatitis (GLP-1s)
• Cholelithiasis or cholecystitis history
• Inflammatory bowel disease (GLP-1s)
• Severe gastroparesis
• Renal impairment (dose adjustment may be needed)
• Hepatic impairment
• History of suicidal ideation

Elderly Patients:

• Start lower doses
• Slower titration
• Enhanced monitoring
• Consider comorbidities
• Sarcopenia risk (favor muscle-preserving protocols)

Diabetic Patients:

• Excellent candidates for GLP-1s
• May need insulin/sulfonylurea dose reduction
• Monitor glucose closely during initiation
• GH peptides: monitor glucose impact

PCOS Patients:

• Often excellent responders
• Metabolic improvements beyond weight
• Consider metformin combination
• Monitor androgen levels

Prescribing Protocols and Dosing Guidelines

Practical prescribing information for safe, effective peptide therapy.

General Prescribing Principles

1. Start Low, Go Slow: Minimize side effects, improve tolerance
2. Titrate Based on Response: Individual optimization
3. Maintain Effective Dose: Not always maximum dose
4. Monitor Consistently: Early detection of issues
5. Adjust Proactively: Address side effects or plateaus promptly

GLP-1 Agonist Prescribing

Semaglutide:

Initial Prescription: 5mg vial (provides ~8-10 weeks at lower doses)

Dosing Schedule:
- Weeks 1-4:    0.25mg SC weekly
- Weeks 5-8:    0.5mg SC weekly
- Weeks 9-12:   1.0mg SC weekly
- Weeks 13-16:  1.7mg SC weekly (if needed)
- Weeks 17+:    2.4mg SC weekly (maximum)

Administration: Subcutaneous injection (abdomen, thigh, upper arm)
Storage: Refrigerate; protect from light

Side Effect Management:

• GI symptoms: Slower titration, dietary modifications, anti-emetics PRN
• Injection site reactions: Rotate sites, proper technique
• Fatigue: Usually temporary, ensure adequate nutrition

Tirzepatide:

Initial Prescription: 25mg vial

Dosing Schedule:
- Weeks 1-4:    2.5mg SC weekly
- Weeks 5-8:    5mg SC weekly
- Weeks 9-12:   7.5mg SC weekly
- Weeks 13-16:  10mg SC weekly
- Weeks 17-20:  12.5mg SC weekly (if needed)
- Weeks 21+:    15mg SC weekly (maximum)

Administration: Subcutaneous injection
Storage: Refrigerate

Growth Hormone Pathway Prescribing

CJC-1295 + Ipamorelin Spray:

Prescription: 50ml sublingual spray

Dosing: 0.5-1ml (one spray) sublingual nightly before bed
Duration: Ongoing for sustained benefits
Storage: Refrigerate

Alternative Injectable Protocol:
- CJC-1295: 100-200mcg SC
- Ipamorelin: 100-200mcg SC
- Frequency: 5-7x weekly before bed

Tesamorelin:

Prescription: Injectable 10mg or 5mg/ml (3.6ml) or Spray 60ml

Dosing: 2mg SC daily (abdominal injection preferred)
Duration: Minimum 6 months for visceral fat reduction
Storage: Refrigerate
Monitoring: Baseline and 3-month imaging for visceral fat

AOD 9604:

Prescription: Capsules (30 count) or as part of BOCA Trimm

Dosing: 300-600mcg daily (divided or single dose)
Route: Oral capsule or SC injection
Duration: 12+ weeks minimum

Novel Peptide Prescribing

Tesofensine:

Prescription: Compounded capsules

Dosing Schedule:
- Weeks 1-2:    0.25mg PO daily (assess tolerance)
- Weeks 3-4:    0.5mg PO daily (therapeutic for most)
- Weeks 5+:     0.75-1mg PO daily (if needed and tolerated)

Timing: Morning (to avoid insomnia)
Monitoring: BP and HR at each visit; baseline ECG

BOCA Trimm (5-Amino-1MQ + NMN + Berberine + AOD 9604 + Laxogenin):

Prescription: 30 capsules

Dosing: 1-2 capsules daily with meals
Duration: 8-12 weeks minimum, ongoing for sustained benefit

Prescription Writing Tips

Sample Prescription – Semaglutide:

Semaglutide 5mg/ml for injection
Disp: 5ml vial
Sig: Inject 0.25mg (0.05ml) subcutaneously once weekly for 4 weeks,
     then 0.5mg (0.1ml) weekly for 4 weeks,
     then 1mg (0.2ml) weekly for 4 weeks,
     then 1.7mg (0.34ml) weekly thereafter.
Refills: 0 (reassess every 2-3 months)

Sample Prescription – CJC-1295 + Ipamorelin Spray:

CJC-1295/Ipamorelin Sublingual Spray
Disp: 50ml bottle
Sig: Spray 0.5-1ml under tongue nightly before bed
Refills: 2

Monitoring and Safety Management

Comprehensive monitoring ensures safety and optimizes outcomes.

Baseline Assessment

Before Initiating Peptide Therapy:

Laboratory Testing:

• Complete Metabolic Panel (CMP)
• Hemoglobin A1c
• Fasting glucose and insulin
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Thyroid function (TSH, Free T3, Free T4)
• Complete Blood Count (CBC)
• Liver function tests (AST, ALT, bilirubin)
• For GLP-1s specifically: Lipase, calcitonin (if family history concerning)
• For GH peptides: IGF-1, fasting insulin

Clinical Assessment:

• Height, weight, BMI calculation
• Blood pressure, heart rate
• Body composition analysis (DEXA, InBody, or similar)
• Waist circumference
• Medical history review
• Contraindication screening
• For tesofensine: ECG

Patient Education:

• Mechanism of action
• Expected timeline
• Potential side effects
• Administration technique
• Lifestyle expectations
• Cost and commitment

Ongoing Monitoring Schedule

Monthly (First 3 Months):

• Weight, blood pressure, heart rate
• Body composition (if available)
• Side effect assessment
• Adherence evaluation
• Dose adjustment as needed

Quarterly (After Initial 3 Months):

• Weight, vital signs, body composition
• Laboratory testing:
  • CMP, HbA1c, lipids
  • For GH peptides: IGF-1
  • For tesofensine: Ongoing BP/HR monitoring
• Clinical assessment
• Goal review and protocol adjustment

Annual:

• Comprehensive metabolic panel
• Complete blood count
• Thyroid function
• Consider DEXA scan
• Cardiovascular risk assessment

Side Effect Management

GLP-1 Agonists – Common Issues:

Serious AEs (Rare but Important):

• Pancreatitis: Severe abdominal pain → stop medication, immediate evaluation
• Gallbladder issues: RUQ pain → imaging, surgical consultation if needed
• Severe gastroparesis: Persistent vomiting → stop medication, GI referral

Growth Hormone Peptides – Common Issues:

• Water retention: Mild, temporary → reassurance, monitor
• Joint discomfort: Rare → dose reduction
• Increased appetite (some GHRPs): Timing adjustment, switch peptides

Tesofensine – Common Issues:

• Increased HR/BP: Dose reduction or discontinuation if significant
• Dry mouth: Hydration, sugar-free gum
• Insomnia: Earlier dosing, dose reduction
• Constipation: Standard management

When to Adjust or Discontinue

Dose Reduction Indications:

• Intolerable side effects at current dose
• Excessive rate of weight loss (>2-3 lbs/week sustained)
• Significant adverse events

Discontinuation Indications:

• Serious adverse events
• Pregnancy
• Patient request
• Goal weight achieved (transition to maintenance)
• Lack of response after adequate trial
• Non-adherence despite intervention

Maintenance Strategy:

• Many patients benefit from continued therapy at lower doses
• Prevents rebound weight gain
• Maintains metabolic improvements
• Individualize based on patient needs and response

Practice Integration Strategies

Successfully incorporating peptide therapy requires strategic practice development.

Building a Peptide Weight Management Program

Program Components:

1. Initial Consultation (60 minutes)
   • Comprehensive assessment
   • Goal setting
   • Treatment plan development
   • Informed consent
   • Fee: $200-400
2. Follow-Up Visits (20-30 minutes)
   • Progress assessment
   • Dose adjustments
   • Side effect management
   • Lifestyle counseling
   • Fee: $100-200
3. Monthly Program Fee Option
   • Includes consultations, monitoring, support
   • Medication additional (transparent pricing)
   • Simplified billing
   • Fee: $300-500/month

Staffing Considerations:

• Medical assistant: Vital signs, injections if needed, patient education
• Nutritionist/health coach: Lifestyle support (optional but valuable)
• Office manager: Scheduling, billing, medication ordering

Marketing Your Peptide Program

Positioning:

• “Medical Weight Loss Using Advanced Peptide Therapy”
• “Evidence-Based Weight Management with Pharmaceutical-Grade Peptides”
• “Comprehensive Metabolic Health Optimization”

Educational Content:

• Patient education materials
• Website content explaining peptides
• Before/after testimonials (with consent)
• Webinars or seminars
• Social media content

Referral Development:

• Other physicians (PCPs, endocrinologists)
• Fitness trainers
• Nutritionists
• Health coaches
• Patient referrals (incentivize)

Documentation and Compliance

Medical Record Documentation:

• Comprehensive H&P
• Treatment rationale
• Informed consent (detailed for off-label use)
• Progress notes at each visit
• Adverse events
• Dose changes and rationale

Informed Consent Elements:

• Off-label use (if applicable)
• Compounded medication (not FDA-approved in finished form)
• Potential risks and benefits
• Alternative treatments
• Cost and commitment
• Patient signature

Prescribing Compliance:

• Valid patient-provider relationship
• Appropriate medical indication
• State-specific prescribing laws
• DEA compliance if applicable
• Prescription monitoring programs

Financial Model

Revenue Streams:

• Consultation fees
• Monthly program fees
• Medication markup (ethical, transparent)
• Additional services (body composition, labs)

Cost Considerations:

• Medication costs through compound pharmacy services
• Staff time
• Lab costs (if you absorb)
• Marketing
• Overhead

Typical Margins:

• Peptide medications: 30-50% markup over cost
• Service fees: Nearly 100% margin if efficient
• Combined model often most profitable

Patient Investment:

• Initial month: $500-800 (consultation + medication)
• Ongoing monthly: $300-600 (medication + follow-up)
• Premium protocols: $600-1000/month

Why Compound Pharmacy Services Matter: Quality and Safety

The source of peptides dramatically impacts safety, efficacy, and legal compliance.

The Quality Spectrum: Research Chemicals to Pharmaceutical-Grade

Research Peptides (Never Appropriate for Patient Use):

• Sold “for research purposes only” to evade regulation
• Purity often <90%, unknown contaminants
• NOT sterile (dangerous for injection)
• No quality testing or verification
• Illegal for human consumption
• No regulatory oversight
• Dangerous and unpredictable

Pharmaceutical-Grade Compound Pharmacy Services:

• 98% pharmaceutical-grade purity

• USP 797 sterile compounding for injectables
• Comprehensive testing (potency, purity, sterility)
• FDA-registered suppliers with Certificates of Analysis
• State Board of Pharmacy oversight
• Licensed pharmacists
• Documented quality assurance
• Legal and appropriate for patient care

Why This Matters to Your Practice:

• Patient Safety: Contaminated peptides can cause serious infections or reactions
• Efficacy: Impure or weak peptides won’t produce expected results
• Legal Liability: Prescribing non-pharmaceutical-grade substances creates risk
• Professional Reputation: Quality reflects on your practice
• Ethical Obligation: Patients trust you to provide safe, effective treatment

USP Standards: The Foundation of Quality

USP Chapter 797 – Sterile Compounding (Critical for Injectables):

Environmental Requirements:

• ISO Class 5 primary engineering controls (laminar flow hoods)
• ISO Class 7 buffer rooms
• ISO Class 8 ante-rooms
• Proper air handling, HEPA filtration
• Environmental monitoring and testing

Personnel Requirements:

• Extensive aseptic technique training
• Media fill validation (sterility testing of technique)
• Annual competency assessment
• Proper garbing and hygiene

Quality Testing:

• Sterility testing for high-risk preparations
• Endotoxin testing
• Potency verification
• Beyond-use dating based on stability

Why It Matters: Injectable peptides bypass the body’s natural defenses. Contamination can be life-threatening. USP 797 compliance ensures sterile products.

USP Chapter 795 – Non-Sterile Compounding (Oral, Topical):

• Ingredient quality standards
• Equipment and facility requirements
• Documentation and traceability
• Quality control procedures
• Proper beyond-use dating

State Licensing: Legal Authorization and Oversight

Multi-State Licensing Importance:

• Pharmacy must be licensed in patient’s state of residence
• Each state license requires application, inspection, approval
• Ongoing compliance and renewal
• State Board oversight and accountability

Red Flags:

• Cannot verify state license
• Not licensed in your state or patient’s state
• Evasive about licensing
• Operating from outside the U.S.

Certificates of Analysis: Verifying Quality

What COAs Should Include:

• Identity testing (confirming ingredient is what it claims)
• Purity testing (percentage of active ingredient)
• Potency (strength verification)
• Microbial/endotoxin testing (when appropriate)
• Heavy metals testing
• Lot number and expiration

Your Due Diligence:

• Request COAs for peptides you prescribe
• Verify pharmaceutical-grade ingredients
• Confirm testing documentation
• Partner only with transparent sources

Partnering with Newtropin: Your Compound Pharmacy Services Solution

Successful peptide therapy requires a reliable source of pharmaceutical-grade compounds. Newtropin’s partnership with Formulation Compounding Center provides the quality, breadth, and support your practice needs.

Why Healthcare Providers Choose Newtropin

1. Comprehensive Peptide Portfolio

GLP-1 Receptor Agonists:

• Semaglutide (5mg, 50mg vials, custom concentrations)
• Semaglutide + B6 or B12 (enhanced formulations)
• Semaglutide Spray (60ml sublingual)
• Tirzepatide + B6 or B12 (10mg, 25mg)
• Retatrutide (24mg, 10mg with B6)
• Orforglipron (30 tablets, oral option)

Growth Hormone Pathway:

• CJC-1295 + Ipamorelin Spray (50ml)
• Sermorelin Injectable (1mg/ml, 10ml)
• Tesamorelin Spray (60ml) and Injectable (10mg, 5mg/ml)
• AOD 9604 Capsules (30 caps)

Novel and Emerging:

• Tesofensine (compounded capsules)
• 5-Amino-1MQ (in BOCA Trimm combination)
• SLU-PP-332 / Gym Fuego (proprietary formula)

Synergistic Combinations:

• BOCA Trimm (5-Amino-1MQ + NMN + Berberine + AOD 9604 + Laxogenin)
• GLP Busters (weight management support)
• Super M.I.C. (lipotropic formula)
• Green Jacket (thermogenic)

Supporting Products:

• Laxogenin (muscle preservation)
• Multiple B-vitamin formulations
• Nutritional support products

Result: Everything you need for simple monotherapy or complex combination protocols

2. Pharmaceutical-Grade Quality Assurance

Formulation Compounding Center Standards:

• USP 795, 797, and 800 Certified: Complete compliance across all compounding categories
• State Licensed: 42 states plus Washington, D.C. (active expansion ongoing)
• ISO-Classified Cleanrooms: Proper sterile compounding facilities
• Pharmaceutical-Grade Sourcing: Only FDA-registered suppliers
• Comprehensive Testing: Potency, purity, sterility verification
• Certificates of Analysis: Available for all ingredients
• Complete Documentation: Full traceability and quality records

What This Means for Your Practice:

• Confidence in product safety and efficacy
• Legal compliance and reduced liability
• Consistent, reliable results for patients
• Professional-grade quality reflecting well on your practice

3. Multi-State Access for Your Patients

Current Licensing:

• 42 states plus Washington, D.C.
• Covers majority of U.S. population
• Verifiable licenses in each jurisdiction

Active Expansion:

• Pursuing licenses in additional states
• Committed to expanding access
• Updates provided as new states come online

Shipping:

• Direct to patient (where licensed)
• Temperature-controlled when needed
• Discreet packaging
• Tracking provided

4. Competitive Pricing Enabling Patient Access

Cost Comparison:

Value Proposition for Patients:

• 60-75% cost savings on GLP-1s
• Access to combinations not commercially available
• Pharmaceutical quality without brand-name prices
• Improved treatment accessibility

Value Proposition for Your Practice:

• Offer effective treatments patients can afford
• Differentiate from practices limited to commercial products
• Ethical markup opportunity
• Reduce patient cost barriers to adherence

5. Professional Support and Education

Provider Resources:

• Clinical protocols and dosing guidelines
• Patient education materials
• Prescribing support
• Continuing medical education opportunities
• Practice development consultation

Pharmacist Access:

• Licensed pharmacists available for consultation
• Medication questions and guidance
• Compounding customization
• Safety and interaction screening

Responsive Service:

• Dedicated provider support team
• Quick response to inquiries
• Prescription processing efficiency
• Problem resolution

6. Custom Formulation Capabilities

Standard Formulations:

• Extensive catalog of ready-to-order peptides
• Proven formulations optimized for efficacy

Custom Compounding:

• Adjust concentrations for specific patients
• Combine peptides in unique ways
• Accommodate allergies or sensitivities
• Create practice-specific protocols

Innovation:

• Early access to emerging compounds
• New formulation development
• Staying ahead of the curve

How to Partner with Newtropin

Step 1: Provider Enrollment

• Complete provider registration
• Verify medical license and credentials
• Review partnership terms
• Establish prescribing privileges

Step 2: Practice Setup

• Access provider portal/ordering system
• Review product catalog
• Establish patient education protocols
• Plan marketing and launch

Step 3: Patient Prescribing

• Patient consultation and evaluation
• Write prescriptions for appropriate peptides
• Submit to Newtropin/Formulation Compounding Center
• Prescriptions processed and fulfilled

Step 4: Ongoing Support

• Regular follow-up with patients
• Dose adjustments as needed
• Access to pharmacist consultation
• Practice development support

Getting Started

Contact Newtropin:

• Phone: (866) 206-1806
• Email: info@newtropin.com
• Website: www.newtropin.com

Provider Portal Access:

• Request access credentials
• Review complete product catalog
• Place orders efficiently
• Track patient prescriptions

Educational Resources:

• Request provider information packet
• Schedule consultation call
• Attend upcoming provider webinars
• Join provider network

Conclusion: The Future of Weight Management is Multi-Modal

Obesity is a complex, chronic disease requiring sophisticated, individualized treatment approaches. The era of simple “eat less, move more” advice or even monotherapy pharmaceutical intervention is giving way to comprehensive, multi-modal protocols that address the full spectrum of metabolic dysfunction.

Peptide therapy—when properly prescribed, sourced, and monitored—represents the most powerful pharmacological tool available for weight management. The key is understanding:

• Which peptides work through which mechanisms
• How to strategically combine them for synergistic effects
• Appropriate patient selection and contraindication screening
• Proper dosing, titration, and monitoring protocols
• The critical importance of pharmaceutical-grade quality

Your Competitive Advantage

Incorporating comprehensive peptide therapy into your practice provides:

✓ Clinical Differentiation: Offer what most providers cannot ✓ Superior Patient Outcomes: Multi-pathway protocols outperform monotherapy ✓ Practice Growth: Meet surging patient demand for effective weight loss ✓ Financial Opportunity: Profitable service line with recurring revenue ✓ Professional Satisfaction: Help patients achieve life-changing results

Why Partnership with Newtropin Matters

Success requires more than just knowledge—it requires access to:

• Pharmaceutical-grade peptides from certified compound pharmacy services
• Comprehensive product portfolio enabling any protocol design
• Multi-state licensing serving your patient base wherever they live
• Competitive pricing making treatment accessible
• Professional support helping you succeed

Newtropin and Formulation Compounding Center provide this complete solution.

Take the Next Step

The weight loss peptide revolution is here. Your patients are asking about semaglutide, tirzepatide, and emerging therapies. They’re seeing results in friends, family, and media coverage. The question is whether they’ll access these treatments through your practice or seek care elsewhere.

Partner with Newtropin to:

• Build a comprehensive peptide weight management program
• Access pharmaceutical-grade compound pharmacy services
• Offer affordable alternatives to expensive brand-name drugs
• Create innovative combination protocols
• Support your patients’ success with quality and expertise

Contact us today to get started:

• Phone: (866) 206-1806
• Email: info@newtropin.com
• Website: www.newtropin.com

Appendix: Quick Reference Resources

Peptide Quick Reference Chart

Monitoring Schedule Template

Baseline:

• Labs: CMP, HbA1c, lipids, TSH, CBC, liver function
• Vitals: BP, HR, weight, BMI
• Body composition: DEXA or InBody
• Assessment: Medical history, contraindications

Monthly (Months 1-3):

• Weight, BP, HR
• Side effects
• Adherence
• Dose adjustment

Quarterly:

• Repeat baseline labs
• Body composition
• Clinical assessment

Annual:

• Comprehensive evaluation
• Imaging if indicated
• Long-term safety assessment

Common Side Effect Management

Nausea (GLP-1s):

1. Slow titration (extend each dose level)
2. Small, frequent meals
3. Avoid high-fat foods initially
4. Ginger or peppermint
5. Ondansetron 4-8mg PRN
6. Usually resolves in 2-4 weeks

Constipation:

1. Increase fiber (25-30g daily)
2. Hydration (64+ oz water)
3. Physical activity
4. Stool softener (docusate)
5. Polyethylene glycol if needed

Injection Site Reactions:

1. Rotate sites consistently
2. Room temperature medication
3. Proper technique
4. Warm compress after
5. Consider site changes

→ Dive Deeper: Weight Loss Peptide Safety Guide: Side Effects, Monitoring & Medical Supervision – Complete safety protocols, adverse event management, contraindications, and pharmaceutical-grade quality standards.

Explore the Complete Weight Loss Peptide Series

This pillar guide provides a comprehensive overview. Dive deeper into specific topics with our detailed cluster pages:

Complete Guide to Semaglutide, Tirzepatide & Retatrutide

Deep dive into GLP-1 receptor agonists with detailed prescribing protocols, titration schedules, side effect management, cost comparisons, and patient selection criteria for all GLP-1 options including compounded formulations.

Growth Hormone Peptides for Fat Loss & Body Recomposition

Complete clinical protocols for CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, and AOD 9604. Learn body recomposition strategies, muscle preservation techniques, and combination approaches with GLP-1 therapy.

Emerging Weight Loss Peptides: Tesofensine, 5-Amino-1MQ & Novel Compounds

Cutting-edge peptide therapy including tesofensine (triple reuptake inhibitor), 5-Amino-1MQ (NNMT inhibitor), exercise mimetics, and emerging compounds available through compound pharmacy services before commercial release.

Custom Weight Loss Peptide Protocols: Combining Peptides for Maximum Results

Five complete protocol strategies from budget-conscious to comprehensive approaches. Includes phased treatment plans, personalization by age/gender/comorbidity, and practical implementation guidance.

Weight Loss Peptide Safety Guide: Side Effects, Monitoring & Medical Supervision

Comprehensive safety resource covering side effect management, monitoring protocols, contraindications, special populations, pharmaceutical-grade quality standards, and emergency protocols.

This comprehensive guide provides the foundation for successful peptide weight management practice. Partner with Newtropin to access the pharmaceutical-grade compound pharmacy services, extensive product portfolio, and professional support you need to deliver exceptional patient outcomes.

Ready to get started? Contact Newtropin today:

• Phone: (866) 206-1806
• Email: info@newtropin.com
• Website: www.newtropin.com

All peptide products require valid prescriptions from licensed healthcare providers. Compounded medications are prepared by state-licensed pharmacies but are not FDA-approved finished products. Newtropin partners with Formulation Compounding Center for compound pharmacy services. See state licensing disclosure for complete availability information.